News

Med-X Secures Coveted OMRI Listing for Nature-Cide All-Purpose Commercial Concentrate to Allow for Use in Certified Organic Food Processing Facilities

Leading Organic Trade Organization Lists Nature-Cide All-Purpose Commercial Concentrate as Allowed for the Use in Accordance with the National Organic…

3 weeks ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Company Achieves Milestones in Both Clinical ProgramsInitiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by…

3 weeks ago

CBD Life Sciences, Inc. (CBDL) Positioned for Unmatched Growth as Trump Welcomes Weed Legalization and Federal Rescheduling

The global cannabis market size was valued at USD 43.72 billion in 2022 and is projected to grow from USD…

3 weeks ago

Modular Medical Announces Results from a Successful GLP-1 Proof of Concept Study

-Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid…

3 weeks ago

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…

3 weeks ago

TRNR Announces 1-for-100 Reverse Split

Split Becomes Effective Monday, November 11, 2024Shareholder- and Board-Approved Action Reduces Shares Outstanding to 313,235 from 31 Million, Ensures Continued…

3 weeks ago

Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates

Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product…

3 weeks ago

Promising cooperation between medac and chiron for the development of organ-on chip technology

WEDEL, Germany, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Testing new substances in animals is a regulatory cornerstone of drug development.…

3 weeks ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial…

3 weeks ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024

Conference Call Scheduled for Thursday, November 14, 2024 at 9:00 AM ETPORTLAND, Maine, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell…

3 weeks ago